Loading news...
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
McKesson (MCK) concluded the recent trading session at $814.63, signifying a -1.13% move from its prior day's close.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
McKesson (MCK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Cerity Partners LLC trimmed its position in McKesson Corporation (NYSE: MCK) by 1.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 56,955 shares of the company's stock after selling 819 shares during the period. Cerity Partners LLC's
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #AI--Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company's total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma compa.
CX Institutional grew its holdings in McKesson Corporation (NYSE: MCK) by 214.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,595 shares of the company's stock after purchasing an additional 9,275 shares during the quarter. CX Institutional's holdings in McKesson
Defense stocks rise as US seizes former Venezuelan president. Jim Lebenthal recommends Lockheed Martin, Stephen Weiss suggests QXO, and Joe Terranova selects McKesson.
McKesson posts a strong fiscal second quarter, lifts full-year EPS outlook, and shows how specialty growth and automation are reshaping its earnings power.
CNBC's “Halftime Report” Investment Committee discuss their top stocks to watch for the second half of the day's trading session.
Golden State Equity Partners lifted its stake in shares of McKesson Corporation (NYSE: MCK) by 116.5% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,009 shares of the company's stock after buying an additional 1,081 shares during the period. Golden State Equity
Henry Schein (NASDAQ: HSIC - Get Free Report) and McKesson (NYSE: MCK - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership. Risk and Volatility Henry Schein has a beta of
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
E. Ohman J or Asset Management AB raised its position in McKesson Corporation (NYSE: MCK) by 12.2% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 6,513 shares of the company's stock after acquiring an additional 707 shares during the quarter. E. Ohman
Burney Co. cut its stake in shares of McKesson Corporation (NYSE: MCK) by 3.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 59,122 shares of the company's stock after selling 1,847 shares during the quarter. McKesson makes up approximately 1.5%
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
McKesson Corporation is undervalued despite strong revenue growth, margin expansion, and capital returns; I rate it Buy with a $920 target (13.5% upside). MCK's strategy focuses on boosting margins by growing high-margin Oncology & Multispecialty and divesting low-margin Medical-Surgical Solutions. Q2 results confirmed margin expansion: revenue hit a record $103.15B (+10% y/y), EPS beat consensus by 9%, and operating profit rose 26% y/y.
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will release its third quarter fiscal 2026 financial results after market close on Wednesday, February 4, 2026. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The live and archived audio webcast will be available on McKesson's Investor Relations website. About McKesson Corporation McKesson Corporation is a diversified healthcare services l.
The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rate both quantitatively and qualitatively and select the top 10 names from an initial list of nearly 400 dividend stocks. The final list of ten stocks is chosen based on sector diversity, high-growth quality scores, and positive momentum, and is suitable for investors in the accumulation phase.
Astoria Portfolio Advisors LLC. bought a new stake in McKesson Corporation (NYSE: MCK) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 905 shares of the company's stock, valued at approximately $684,000. Other institutional investors and hedge funds have